UNSPSC 51124003: Flecainide

This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C17H20F6N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) K94FTS1806, chemically known as n-(2-piperidylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide but more generally known as flecainide, which bears US NIH Compound Identifier 3356. European Medicines Agency schedules Flecainide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07637MIG.

UNSPSC 51124003 Flecainide (Commodity) covers pharmaceutical-grade flecainide products and chemically equivalent generic formulations procured by state and local government healthcare providers and pharmacy benefit programs. State and local governments buy flecainide under this code primarily as part of broader advanced life support medication purchases by emergency medical services and fire rescue departments, and through cooperative purchasing agreements that aggregate generic pharmaceuticals across multi-state government healthcare systems. Issuing bodies span city fire departments, state health and human services commissions, and regional cooperative purchasing alliances representing multiple state and local jurisdictions.

Recent activity includes the City of Tampa's Purchasing Department issuing IFB 26P00188 for Advanced Life Support Medications (due April 8, 2026) seeking multiple vials and injections including Epinephrine, Diltiazem, Adenosine, and Labetalol for use by Tampa Fire Rescue in Hillsborough County, Florida, with an estimated contract value of $40,000 and a one-year term plus optional renewals; the Texas Health and Human Services Commission issuing RFI HHS0017013 (response deadline April 3, 2026) to explore direct-to-manufacturer pharmacy prescription fulfillment models; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issuing RFP S1070000015802 (proposals due March 26, 2026) to establish contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with awards effective July 1, 2026, and a two-year initial contract term. Geographic activity is present in Florida, Texas, and the upper Midwest; the cooperative purchasing vehicle represents the most significant procurement mechanism for commodity pharmaceuticals under this code.